Mizuho raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $23 from $20 and keeps a Neutral rating on the shares. The District Court of Delaware ruled in Acadia’s favor on the patent infringement case against Aurobindo Pharma, the analyst tells investors in a research note. The firm cites the favorable district court ruling for the target raise but still has concerns about Daybue adoption.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $31 from $28 at Baird
- ACADIA Pharmaceuticals’ Legal Victory and Pipeline Expansion Drive Buy Rating and Increased Price Target
- Acadia Pharmaceuticals price target raised to $32 from $27 at H.C. Wainwright
- Acadia court ruling alleviates overhang for Nuplazid, says RBC Capital
- Acadia confirms court ruling in favor of Nuplazid formulation patent